Who
Kary Eldred
Director
Company insider
Files Form 4 as: Director, Galectin Therapeutics.
In numbers
- Trades disclosed
- 27
- Buys
- 14
- Sells
- 0
- Bought
- $56K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 22 May 2018
- Last trade
- 6 Feb 2026
- Last filed
- 9 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Feb 2026filed 9 Feb 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $810300 at $2.70 | filing |
| 6 Feb 2026filed 9 Feb 2026 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $810300 at $2.70 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 23 Dec 2025filed 23 Dec 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,611700 at $3.73 | filing |
| 23 Dec 2025filed 23 Dec 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,611700 at $3.73 | filing |
| 21 Jul 2025filed 22 Jul 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,9301,000 at $2.93 | filing |
| 23 Jan 2025filed 27 Jan 2025 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 24 Dec 2024filed 26 Dec 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $11K13,469 at $0.82 | filing |
| 23 Oct 2024filed 23 Oct 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,300500 at $2.60 | filing |
| 22 Jul 2024filed 23 Jul 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $956400 at $2.39 | filing |
| 24 Jan 2024filed 7 Feb 2024 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 16 Jan 2024filed 23 Jul 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $956400 at $2.39 | filing |
| 16 Jan 2024filed 16 Jan 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $895500 at $1.79 | filing |
| 19 Jul 2023filed 20 Jul 2023 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,8601,598 at $1.79 | filing |
| 21 Feb 2023filed 21 Feb 2023 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,5901,000 at $1.59 | filing |
| 26 Jan 2023filed 30 Jan 2023 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 Jan 2023filed 26 Jan 2023 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,4431,300 at $1.11 | filing |
| 24 Jan 2022filed 25 Jan 2022 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 25 Mar 2021filed 29 Mar 2021 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.